To schedule a free and confidential consultation call 888.384.2588 or click here.

Our Nationwide Success

Over the course of their careers, including at prior firms, our attorneys have worked on scores of successful cases, including the following (listed alphabetically):

Astellas

In a non-intervened case, Astellas paid $18 million as part of a settlement agreement in a case involving allegations that Astellas underpaid rebates owed under the Medicaid Drug Rebate Program by reporting inaccurate pricing information to the government. Link to case

AstraZeneca, Cephalon, Genzyme, & Biogen

In a series of cases in which the government declined to intervene, settlements were negotiated with four separate drug manufacturers for over $60 million relating to allegations that the manufacturers defrauded Medicaid by underpaying certain Medicaid rebates. Link to case

AstraZeneca (Seroquel)

AstraZeneca LP and AstraZeneca Pharmaceuticals LP agreed to pay $520 million to resolve claims that the company marketed the antipsychotic drug Seroquel for unapproved uses and paid kickbacks to doctors to promote the drug for those purposes. Link to case

Bristol Myers Squibb

In a case in which the government declined to intervene, Bristol Myers Squibb agreed to pay $75 million to resolve allegations that the company underpaid rebates owed under the Medicaid Drug Rebate Program by reporting inaccurate pricing information to the government. Link to case

Eli Lilly and Company (Zyprexa)

Eli Lilly and Company agreed to pay more than $1.4 billion to resolve claims that the company marketed the antipsychotic drug Zyprexa for unapproved uses. Link to case

Johnson & Johnson (Risperdal)

Johnson & Johnson, partially through its subsidiaries, agreed to pay more than $2.2 billion to resolve allegations that the company promoted Risperdal for unapproved uses, including by targeting children and the elderly despite knowing the product was not approved for their use. Link to case

King Pharmaceuticals

King Pharmaceuticals agreed to pay $124 million to resolve allegations it underpaid rebates owed to the Medicaid program. It was alleged that the company misreported the average manufacturer price and best prices for its Medicaid-reimbursed drugs in violation of the Medicaid Rebate Statute. Link to case

Kool Smiles Denistry P.C.

Dental management company Benevis LLC agreed to pay $23.9 million to resolve allegations it violated the False Claims Act by submitting false claims for payment to state Medicaid programs for medically unnecessary pediatric dental services provided by its “Kool Smiles” dental clinics. Link to case

Merck & Company (Zocor, Vioxx, and Pepcid)

Merck & Company agreed to pay more than $650 million to resolve allegations it paid illegal kickbacks to doctors to prescribe its products and that it reported knowingly reported false and fraudulent prices to the government for its drugs Zocor, Vioxx, and Pepcid in violation of the Medicaid Rebate Statute. Link to case

NextCare

Urgent care services provider NextCare agreed to pay $10 million to resolve allegations it submitted false claims for payment to state and federal insurance programs by billing for unnecessary allergy, flu, and respiratory testing. Link to case

Omnicare, Inc.

In two cases in which the government declined to intervene, defendant Omnicare agreed to pay $124 million to settle False Claims Act cases alleging that the company defrauded the government by paying kickbacks to nursing homes to refer back patients. Link to case

Wyeth and Pfizer, Inc. (Protonix)

Wyeth and Pfizer Inc. agreed to pay $784 million to settle Medicaid rebate fraud claims related to its acid-reflux drug Protonix. Wyeth was alleged to have knowingly reported to the government false and fraudulent prices for two different versions of the Protonix drug in violation of the Medicaid Rebate Statute. Link to case

To schedule a free and confidential consultation call 888.384.2588 or click here.